Clinical trial · Interventional
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
A Pilot Study of Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
NCT00355407CI-TRIAL-00002129completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Darbepoetin alfa | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluate the percentage of patients achieving a target hemoglobin of 11 g/dL or greater by day 100 following allogeneic stem cell transplantation.
Secondary outcomes (2)
- measure
- Evaluate the percentage of patients achieving a greater than 1 g/dL hemoglobin increase between days 30 and 100 after allogeneic stem cell transplantation
- measure
- record transfusion requirements between days 30 and 100 in patients undergoing darbepoetin alfa administration following allogeneic stem cell transplantation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Hematologic malignancies undergoing ablative allogeneic stem cell transplantation for any indication * 18 years of age or older * Hgb of less than 10 g/dL at the time of initiation therapy Exclusion Criteria: * Known hypersensitivity reaction to darbepoetin alfa or any of its components * Transfusion of packed red blood cells within 3 days of initiation of treatment with darbepoetin alfa * Any history of grade III or IV GVHD * Use of any erythropoietic growth factor since transplantation * Uncontrolled hypertension * History of seizure * Baseline creatinine greater than 2 * Dialysis dependence at the time of enrollment * Hemolytic uremic syndrome * Active GI bleeding * Concurrent autoimmune hemolytic anemia * Concurrent unstable angina * History of congenital hypercoagulable state or previous venous or arterial thrombosis * Relapsed disease prior to the initiation of study treatment * History of renal cell carcinoma
References
Publications (0)
Data not yet available
No reference posted for this study.